Employment and Workforce - In 2025, Kohl's employed an average of approximately 84,000 associates, including about 29,000 full-time and 55,000 part-time associates[19]. - The company maintains a commitment to competitive compensation, offering a 100% match in the 401(k) Savings Plan up to 5% of pay after one year of employment[24]. - Kohl's has a strong focus on employee wellness, providing various mental well-being and personal growth benefits, including counseling sessions and proactive coaching[25]. - The company emphasizes a culture of inclusion and belonging, with over 8,500 members in its Business Resource Groups[22]. - Kohl's is committed to ethical standards and requires annual ethics training for all associates[28]. Financial Commitments and Risks - The company has no significant long-term purchase commitments with any suppliers, and no vendor accounted for more than 10% of net purchases in 2025[31]. - Kohl's is subject to interest rate risk from its $1.5 billion revolving credit facility, which bears interest at a variable rate based on SOFR plus the applicable margin[211]. - The remaining $425 million of notes outstanding issued in March 2021 include coupon rate step-ups if the long-term debt is downgraded below a BBB- credit rating, which has occurred in 2023, 2024, and 2025[210]. Business Operations - The retail business is subject to seasonal influences, with sales typically higher during back-to-school and holiday seasons[32]. - Kohl's has over 200 registered trademarks, which are considered valuable to the business[33].

Revenue Performance - Tenon Medical, Inc. reported unaudited revenue for Q4 2025 of $1.45 to $1.48 million, representing a 90% year-over-year increase compared to Q4 2024[4] - For the fiscal year 2025, the company reported unaudited revenue of $3.91 to $3.94 million, reflecting a 20% year-over-year increase compared to fiscal year 2024[4] Future Financial Reporting - The company plans to release detailed financial results for Q4 and full year 2025 on March 19, 2026, after market close[5]

Offering Details - Zura Bio Limited is offering 18,200,000 Class A Ordinary Shares and pre-funded warrants to purchase up to 1,800,000 Class A Ordinary Shares[1] - The offering includes an option for underwriters to purchase an additional 3,000,000 Ordinary Shares[1] - The purchase price for the Pre-Funded Warrants is set at $6.249 per warrant, with a withholding of $0.375 per warrant for offsets[83] - The initial public offering price per Ordinary Share is set at $6.25, while the price per Pre-Funded Warrant is $6.249[160] - The purchase price per Ordinary Share for the Underwriters is $5.875, which is $0.375 less than the initial public offering price[161] - The company has granted an option to the Underwriters to purchase up to an additional 3,000,000 Ordinary Shares[164] - The total number of shares allocated to Leerink Partners LLC is 7,280,000, while Piper Sandler & Co. and Cantor Fitzgerald & Co. received 5,278,000 and 4,550,000 shares respectively[162] - The total number of Pre-Funded Warrants allocated is 1,800,000, with 720,000 going to Leerink Partners LLC[162] Regulatory Compliance - The company has filed a shelf registration statement on Form S-3, which was declared effective on September 17, 2024[2] - The Ordinary Shares are registered under Section 12(b) of the 1934 Act and listed on the Nasdaq Stock Market[19] - The company has complied with the reporting requirements of Section 13 or Section 15(d) of the 1934 Act[19] - The company has filed a Notification of Listing of Additional Shares with Nasdaq regarding the Securities[19] - The interactive data included in the Registration Statement has been prepared in accordance with the Commission's rules and guidelines[17] - The Company is not classified as an "investment company" under the Investment Company Act of 1940[28] - There are no registration rights for any equity or debt securities of the Company that would affect the current offering[36] - The Company is in compliance with all material aspects of the Employee Retirement Income Security Act (ERISA) and has no reportable events expected regarding its employee benefit plans[52] - The Company is compliant with the Sarbanes-Oxley Act of 2002, with no known failures in compliance by its directors or officers[53] - The Company and its Subsidiaries are in compliance with all applicable laws and regulations, including those from the FDA and EMA, with no material adverse effects expected[61] - The Company has filed all required documents with the Commission pursuant to the 1934 Act within the specified time periods[94] Financial Condition - There has been no material adverse change in the Company's business or financial condition since the last reporting date[35] - No material liabilities or obligations have been incurred by the Company that would adversely affect its financial condition[35] - The financial statements of the Company and its Subsidiaries present a fair consolidated financial position and results of operations in compliance with GAAP[37] - The Company has filed all required tax returns and paid all taxes due, with no material tax deficiencies asserted against it[42] - The Company has no material outstanding loans or related party transactions that have not been disclosed[65] - The Underwriters have the right to terminate the Agreement if there is a material adverse change in the Company's financial condition or market conditions[134] Corporate Structure and Governance - The Company is duly incorporated and in good standing under the laws of the Cayman Islands, with full corporate power to conduct its business[21] - Each Subsidiary is validly existing and in good standing under its jurisdiction, with all issued share capital fully paid and owned by the Company[23] - The Company has authorized and outstanding capitalization as described in the Registration Statement, with all shares validly issued and free of encumbrances[24] - The Securities to be purchased by the Underwriters have been duly authorized and will be validly issued and fully paid upon delivery[25] - The Company has established effective internal accounting controls and disclosure controls, with no material weaknesses reported[48] - The Company has good and marketable title to all material properties, free of encumbrances that would affect their value[45] Legal and Insurance Matters - There are no pending legal proceedings that could materially affect the Company's ability to perform its obligations[38] - The Company and its Subsidiaries maintain adequate insurance coverage for their businesses, including clinical trial liability claims[44] - There are no ongoing legal proceedings that could materially affect the Company or its Subsidiaries[64] - The Company has not received any adverse findings or notices from governmental authorities regarding compliance with applicable laws[61] Intellectual Property - The Company owns or possesses rights to all necessary intellectual property for its business operations, with no known challenges to its rights[59] - The Company's patents have been duly maintained and are in full force, with no adjudged invalid or unenforceable patents since in-licensing[59] - The Company has taken reasonable steps to secure its interests in intellectual property and protect confidential information[59] - The Company is not bound by any agreements that materially restrict its use of intellectual property[59] Operational Compliance - The Company has conducted all non-clinical studies and clinical trials in accordance with applicable laws and protocols, with no material serious adverse events reported[62][63] - The Company has maintained compliance with privacy and data protection laws, with no significant security breaches reported in the past three years[68] - The Company has established disaster recovery and security plans for its IT assets, consistent with industry standards[68] - The Company is in compliance with all applicable health care laws and has not received any claims or actions alleging violations[73] Agreement and Indemnity - The Company agrees to indemnify Underwriters against any losses arising from untrue statements or omissions in the Registration Statement[120] - The Company must provide additional documents and opinions as required by the Underwriters to ensure compliance with the issuance and sale of Securities[118] - The Company is obligated to provide a Bring-down Comfort Letter if requested by the Underwriters[116] - The Underwriters may seek contribution from the Company for any losses incurred due to untrue statements or omissions[126] - The Company must notify the Underwriters of any actions commenced against it for which indemnity may be sought[123] - The Company must ensure that all proceedings related to the issuance and sale of Securities are satisfactory to the Underwriters[118] Miscellaneous - The agreement includes provisions for default by Underwriters, allowing for arrangements to be made within 24 hours if any Underwriter fails to purchase the Securities[137] - The agreement is governed by the laws of the State of New York, and any legal proceedings must be instituted in specified courts in New York[148][149] - The time of the agreement is of the essence, with specified times referring to New York City time[150]

Financial Performance - Assembly Biosciences reported a net loss of $6.1 million, or $0.55 per share, for the year ended December 31, 2025, compared to a net loss of $40.2 million, or $6.69 per share, in 2024[11]. - Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, up from $28.5 million in 2024, reflecting a significant increase in collaboration funding[8]. - Cash, cash equivalents, and marketable securities totaled $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of December 31, 2024[8]. - Total assets increased to $257.6 million as of December 31, 2025, compared to $119.2 million in 2024[15]. Expenses - Research and development expenses increased to $64.8 million for the year ended December 31, 2025, from $55.9 million in 2024, driven by spending on the helicase-primase inhibitor program[11]. - General and administrative expenses rose to $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024, primarily due to higher professional fees and stock-based compensation[11]. Licensing and Collaborations - The company successfully licensed its helicase-primase inhibitor program, including candidates ABI-5366 and ABI-1179, to Gilead, receiving a net $35 million option fee[5]. - The company is positioned to opt into a 40% U.S. cost-profit share for the herpesvirus HPI program by mid-2026, pending Gilead's development plan and budget[8]. Clinical Development - Assembly Biosciences anticipates initiating a Phase 2 clinical study for ABI-6250 by the end of 2026, targeting chronic hepatitis delta virus[8]. - The company completed dosing and follow-up for all participants in Phase 1a/b studies for ABI-5366 and ABI-1179[5].

Financial Performance - For the year ended December 31, 2025, Curis reported a net loss of $7.6 million, or $0.58 per share, compared to a net loss of $43.4 million, or $6.88 per share in 2024[9]. - Revenues for the year ended December 31, 2025, were $9.4 million, down from $10.9 million in 2024, with fourth-quarter revenues of $1.1 million compared to $3.3 million in the same period in 2024[10]. - Revenues for the three months ended December 31, 2025, were $1,138 million, a decrease from $3,345 million in the same period of 2024[26]. - The company reported a net loss per common share of $0.58 for the twelve months ended December 31, 2025, improving from a loss of $6.88 in 2024[26]. - Total operating expenses for the twelve months ended December 31, 2025, were $42,345 million, down from $55,450 million in 2024[26]. - Net income for the three months ended December 31, 2025, was $19,356 million, compared to a net loss of $9,618 million in the same period of 2024[26]. Expenses - Research and development expenses decreased to $28.3 million for the year ended December 31, 2025, from $38.6 million in 2024, with fourth-quarter expenses of $5.8 million compared to $9.0 million in 2024[13]. - General and administrative expenses were $14.0 million for the year ended December 31, 2025, down from $16.8 million in 2024, with fourth-quarter expenses of $2.9 million compared to $3.4 million in 2024[14]. Assets and Liabilities - Total assets decreased to $19,966 million as of December 31, 2025, from $41,265 million in 2024[28]. - Total liabilities were $14,504 million as of December 31, 2025, down from $47,263 million in 2024[28]. - Cash and cash equivalents decreased to $5,061 million as of December 31, 2025, from $19,997 million in 2024[28]. - Accounts payable and accrued liabilities increased to $12,886 million as of December 31, 2025, compared to $10,135 million in 2024[28]. - The company maintained goodwill at $8,982 million for both December 31, 2025, and 2024[28]. Cash Position and Financing - As of December 31, 2025, Curis had cash and cash equivalents totaling $5.1 million, with approximately 12.9 million shares of common stock outstanding[17]. - Curis expects its cash runway, including initial gross proceeds of $20.2 million from the January 2026 PIPE Financing, to support operations into the second half of 2027[18]. Clinical Development - Curis initiated a Phase 2 clinical study of emavusertib in combination with zanubrutinib for Chronic Lymphocytic Leukemia (CLL) patients[4]. - The company continues to enroll patients in the TakeAim Lymphoma study, which aims to support filings for accelerated approval in Primary CNS Lymphoma (PCNSL) in the US and Europe[5]. - Emavusertib has received orphan drug designation from both the FDA and EMA for the treatment of PCNSL[5]. Non-Cash Gains - Curis recognized a non-cash gain of $27.2 million in the fourth quarter of 2025 from the release of liability related to the sale of future royalties associated with the sale of Erivedge[15]. - The company reported a gain on the release of liability related to the sale of future royalties of $27,189 million for the twelve months ended December 31, 2025[26].

Financial Performance - Net income for the year ended December 31, 2025 improved to $1,273,000 or $0.06 per diluted share compared to a net loss of $918,000 or ($0.05) per diluted share in the same period of 2024[8] - Total revenue for the full year ended December 31, 2025 increased 13% to $22,666,000 compared to $19,997,000 in the same period of 2024[6] - Adjusted EBITDA improved to $2,566,000 for the year ended December 31, 2025 compared to $520,000 for the same period of 2024[8] - Net income for the fourth quarter improved significantly to $1,552,000 or $0.08 per diluted share compared to net income of $488,000 or $0.03 per diluted share for the same period in 2024[4] - Net income for 2025 was $1,273,000, a significant improvement from a net loss of $918,000 in 2024[19] - Adjusted EBITDA for 2025 reached $2,566,000, compared to $520,000 in 2024, indicating strong operational performance[19] Revenue Growth - Fourth quarter total revenue grew 12% to a record $6,635,000 compared to $5,936,000 in the same period of 2024[1] - Fourth quarter SaaS revenue grew 12% and totaled $6,620,000 compared to $5,913,000 in the same period of 2024[1] - Revenues increased to $22,666,000 in 2025, up from $19,997,000 in 2024, reflecting a growth of approximately 8.3%[22] - Adjusted gross profit for 2025 was $20,999,000, compared to $18,347,000 in 2024, representing an increase of about 9%[22] Operating Expenses - Operating expenses for the year ended December 31, 2025 were $19,414,000 compared to $19,334,000 for the same period of 2024[7] - Operating expenses for the fourth quarter of 2025 decreased by 7% to $4,571,000 compared to $4,928,000 for the same period of 2024[3] - Stock-based compensation expense was $777,000 in 2025, down from $876,000 in 2024[19] Cash Position - Cash balance totaled $9,650,000 at year end December 31, 2025, an increase from $4,666,000 in 2024[9] - Cash provided by operating activities was $4,541,000 in 2025, a turnaround from cash used of $2,694,000 in 2024[16] - Cash and cash equivalents at the end of 2025 totaled $9,650,000, up from $4,666,000 at the end of 2024[16] Accounts Receivable - The company reported a decrease in accounts receivable by $1,165,000 in 2025, compared to an increase of $219,000 in 2024[16] Market Reach - The company is processing identity transactions for nearly half of the adult population in the U.S. and Canada annually, showcasing its market reach[23]

Financial Position - As of December 31, 2025, SELLAS Life Sciences Group, Inc. estimates its unaudited cash and cash equivalents position at $71.8 million[4] - The company received approximately $26.5 million in proceeds from the exercise of common stock warrants after December 31, 2025[5] Share Information - As of January 7, 2026, the company had 170,282,026 shares of common stock outstanding[6]

Financial Performance - Revenue for the fiscal year ended January 31, 2026, was $857.2 million, up from $796.4 million in 2025 and $732.4 million in 2024, indicating a growth trend [82]. - The company has an accumulated deficit of $754.3 million as of January 31, 2026, compared to $626.1 million in 2025, highlighting ongoing financial challenges despite revenue growth [84]. - The company’s financial metrics, including revenue and profitability, have fluctuated in the past and may continue to do so, affecting investor expectations [94]. - The company has $163.0 million in cash and cash equivalents and $339.5 million in highly liquid marketable securities as of January 31, 2026 [354]. - The company may be required to collect additional sales taxes in jurisdictions where it has not historically done so, leading to potential substantial tax liabilities [216]. Market Expansion and Strategy - The company aims to expand its Unified Customer Experience Management (Unified-CXM) platform by investing in research and development, enhancing product features, and improving scalability and security [87]. - The company plans to continue international expansion, targeting new markets outside the United States to increase its customer base and sales [88]. - Approximately 44% of the company's sales during the year ended January 31, 2026, were to customers outside of the Americas, indicating a significant international presence [141]. - The company anticipates increased marketing expenditures as it expands into new markets, which may not yield proportional revenue increases [138]. - The company faces challenges in maintaining its brand reputation, which is crucial for attracting and retaining customers and employees [137]. Operational Risks and Challenges - The company faces risks related to customer renewals and expansion, which are critical for maintaining revenue and financial health [90]. - The company has experienced significant growth in the number of enterprises and end users, which places demands on management and operational resources [88]. - The company faces potential significant costs and service interruptions if data center or cloud computing agreements are terminated or not renewed on commercially reasonable terms [116]. - The company has faced difficulties in managing larger CCaaS projects, leading to increased customer dissatisfaction and delays in revenue recognition [98]. - The company must navigate various risks associated with international operations, including cultural differences and compliance with local regulations [143]. Technology and Innovation - The company utilizes artificial intelligence in its products, which may introduce operational challenges and competitive risks [80]. - The company is investing in AI capabilities, including agentic AI systems, which may expose it to operational challenges and legal liabilities [120]. - The company is incorporating AI into its products through third-party vendors, which may lead to challenges and risks that are difficult to predict [124]. - The company recognizes revenue ratably over the terms of customer contracts, which can delay the reflection of new sales in financial results [107]. - The company’s ability to integrate various data sources is crucial, and changes in third-party API capabilities could negatively impact its value proposition [104]. Compliance and Regulatory Risks - The company faces risks related to compliance with international laws and regulations, which could increase operational costs and impact revenue recognition [145]. - The evolving legal and regulatory landscape regarding AI may require significant resources to ensure compliance, with potential fines of up to €35 million or 7% of total worldwide annual turnover for non-compliance with the EU AI Act [129]. - The company is subject to various export and import controls and economic sanctions laws that could impair its ability to compete internationally [168]. - The company is subject to stringent data privacy and security obligations, with potential consequences including regulatory investigations, litigation, and loss of revenue if compliance is not maintained [180]. - The company faces increasing compliance costs and risks due to stringent data privacy and security laws, such as GDPR and CCPA, which could adversely affect its business operations [192]. Intellectual Property and Legal Risks - The company owns 38 U.S. issued patents and has 10 pending U.S. patent applications as of January 31, 2026, relying on various legal protections for its intellectual property [151]. - The company may incur significant expenses in monitoring and enforcing its intellectual property rights, which could distract management and impair its competitive position [155]. - The company faces potential claims from third parties alleging infringement of their intellectual property rights, which could result in costly litigation and distract from business operations [156]. - The company may face substantial liability for intellectual property infringement due to indemnity provisions in customer agreements [161]. - The company may struggle to establish ownership of intellectual property related to AI technologies, impacting its business model [130]. Financial and Market Risks - The company’s stock price may be volatile due to various factors, including market fluctuations and public perception of its performance [224]. - The company faces risks from unstable market conditions, including geopolitical tensions and economic downturns, which could adversely affect business and share price [236]. - Trade disputes and political tensions may negatively impact customer demand and limit expansion opportunities, affecting overall business operations [238]. - The dual-class structure of the company's stock concentrates voting power with a small group of stockholders, limiting the influence of other shareholders [226]. - Future ownership changes could limit the company's ability to utilize net operating loss carryforwards, adversely affecting profitability [223].

Financial Results - Sky Harbour Group Corporation announced its financial results for the year ended December 31, 2025, in a press release on March 19, 2026[5]. - The company has not disclosed specific financial figures or performance metrics in the provided documents[5][6]. Investor Presentation - The company provided an investor presentation to stakeholders, highlighting key financial metrics and strategic initiatives[6]. - The financial results and investor presentation are intended to be considered alongside the company's filings with the SEC for a comprehensive understanding of its performance[7]. - The report includes an exhibit index referencing the press release and investor presentation as key documents for stakeholders[12]. Forward-Looking Statements - The report includes forward-looking statements that involve risks and uncertainties, cautioning stakeholders against undue reliance on these projections[9]. - The company has no obligation to update or revise forward-looking statements unless new developments arise[9]. Company Classification and Compliance - The company is classified as an emerging growth company, which may affect its reporting and compliance obligations[4]. - The press release and investor presentation are not considered "filed" under the Securities Act or the Exchange Act, limiting their legal implications[8]. Stock Information - The company is listed on the New York Stock Exchange under the trading symbol SKYH for Class A common stock and SKYH WS for warrants[3].

Financial Performance - Revenue for the fiscal year ended January 31, 2026, was $1.32 billion, up from $886.5 million in 2025 and $627.9 million in 2024, indicating significant growth[90]. - The company reported net losses of $(348.8) million, $(1.15) billion, and $(354.2) million for the fiscal years ended January 31, 2026, 2025, and 2024, respectively, with an accumulated deficit of $(3.19) billion as of January 31, 2026[101]. - Subscription revenue includes sales from subscription term-based licenses and SaaS subscriptions, with a shift towards more SaaS revenue recognized ratably over time[141]. - The company has seen an increase in customers opting for annual, monthly, or consumption payments instead of multi-year upfront payments, causing cash flow volatility[162]. - The company expects fluctuations in financial results, making future projections difficult, which could lead to a decline in stock price if expectations are not met[159]. Market and Competitive Landscape - The market for data security and AI solutions is rapidly evolving, and the company's future success will depend on the growth of this market and customer adoption rates[94]. - The competitive landscape in the data security market is intense, with competitors investing in AI technologies to enhance their offerings[145][146]. - Future competition may arise from public cloud providers and SaaS companies developing native data security solutions, increasing market pressure[149]. - The company derives substantially all revenue from its data security platform, emphasizing the need for continued market acceptance and feature development[157]. Customer Dynamics - Customer retention is critical, with a typical subscription period of three years, and some customers may choose not to renew, impacting revenue[104]. - Customer dissatisfaction may arise if Subscription Credits expire unused, potentially harming future operational results[152]. - High-quality customer support is critical for maintaining customer satisfaction; failure to provide effective support could harm customer relationships and future sales[211]. Operational Challenges - The company faces challenges in attracting new customers, particularly in convincing organizations to allocate budgets for its data security and AI solutions[99]. - Increased operating expenses are expected as the company expands its sales, marketing, and product development teams to drive customer adoption and support international growth[101]. - The company faces challenges in attracting and retaining skilled personnel, particularly in engineering and sales, which could impact growth prospects[156]. - Sales cycles are long and unpredictable, particularly with large organizations, which can lead to revenue fluctuations due to extended evaluation processes[172]. Regulatory and Compliance Risks - The company is subject to stringent U.S. and foreign laws regarding privacy and data security, which could lead to regulatory investigations and significant fines[240]. - Under the EU GDPR, companies may face fines of up to €20 million or 4% of annual global revenue, whichever is greater, for non-compliance[243]. - The company is subject to ongoing investigations related to potential violations of federal law concerning government contracts, which could result in substantial fines and reputational harm[209]. Technology and Innovation - The transition to SaaS subscriptions has been largely completed, with a significant majority of new and existing customers adopting RSC on a subscription basis by the end of fiscal 2026[102]. - The company plans to invest substantially in expanding data security product features, generative AI deployment, and international market expansion[92]. - The company is investing in generative AI capabilities, including the Rubrik Agent Cloud, to enhance enterprise AI agent deployments, but faces risks related to legal liability and compliance[132]. Financial Structure and Debt - The company issued $1.15 billion in Notes in June 2025 and repaid $327.9 million under the Amended Credit Facility, which was terminated thereafter[271]. - The company may require additional capital to support growth, which might not be available on favorable terms, particularly during market volatility[225]. - The company’s leverage may require a substantial portion of cash flow from operations to be dedicated to debt payments, limiting its ability to fund operations and pursue growth opportunities[272]. International Operations - The company faces various risks in international operations, including political and economic conditions, regulatory changes, and cultural differences, which could adversely affect financial results[259][261]. - Customers outside the United States generated 30% and 31% of total revenue for fiscal 2026 and 2025, respectively[239]. - The company may need to establish relationships with new Channel Partners to expand into certain international markets[239]. Risk Management - The company has encountered risks associated with operating in a new market for data security and AI solutions, which may affect its ability to achieve profitability[97]. - The company relies on third-party providers for critical business systems, which may expose it to additional cybersecurity risks[118]. - The company maintains insurance for claims associated with its solutions, but coverage may not be adequate, potentially leading to significant financial exposure[219].